Hepatitis C

The evidence regarding patients with entecavir-treated chronic hepatitis B without maintaining virological response is limited and uncertain.

Co-infections of HBV and HIV often lead to an increased risk of overall mortality.

Serum concentrations of aminotransferases improved for HCC-DAA and DAA-HCC groups 1 year following surgery.

Serum HBV DNA significantly decreased from week 0-24 in patients treated with entecavir.

While effective, liver biopsies are invasive and costly for assessing liver fibrosis.

HBeAg loss rate was higher in males and older individuals.

More than half of DAA prescriptions were prescribed by specialists like gastroenterologist and infectious disease physicians.

The cumulative time to curative treatment failure rates of patients who received DAA were 93.6% and 73.2% at 1 and 3 years, respectively.

Italy and the Netherlands both achieved their target HBV control.

Genotype F was the common genotype found at 5.73 per 1000 person-years of follow-up.

Patients with IBD, rheumatoid arthritis, and psoriasis are commonly treated using biologic agents such as infliximab, tofacitinib, and ustekinumab.

A recent study has found statins are underutilized for NASH and NAFLD patients.

The rare liver disease can often lead to liver failure.

The issuance comes within a week of the planned PDUFA date for the drug's possible indication as an adult CKD therapy.

The researchers found sero-protection rate at 12-month was significantly higher in the ID arm compared to the IM cohort.

Biologic use was not associated with an increased risk of hepatitis B virus flares.

More than 56% of these patients enrolled in TARGET-NASH were being treated with statins.

A maternal-infant HCV linkage program in combination with a multidisciplinary clinic to collocate mother and infant care was implemented in 2016.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Sustained virologic response following direct acting antiviral treatment substantially reduced the all-cause mortality rate in patients with HCV.

The expansion for sofosbuvir/velpatasvir is supported by phase 2 data showing an 83% sustained virologic response or cure rate among patients as young as 3 years old.

Direct-acting antivirals has increased the need to treat children HCV patients before they begin to engage in dangerous behaviors.

A recommendation for all adults in the US to be screened for HCV has increased the need for treatment programs in urban areas.

Data show low BMI, male gender, and older age in patients associated with higher overall mortality.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.

Data show males, patients with high BMI correlated with higher FAST score in HCV care.

A large proportion of HCV patients remain undiagnosed, particularly in the older population.

Incidence rates decreased by nearly half after direct-acting antiviral treatment regimen.

An electronic reminding system helped identify 3783 patients with anti-HCV antibody documentation.